重大事件
外國發行人報告
6-K
2026-06-30
Lakefront Biotherapeutics 接獲主要股東 Madison Avenue Partners 持股逾5%通知
AI 繁中摘要
美國證券交易委員會（SEC）6-K 申報文件摘要 📄
**申報類型**：6-K（外國私人發行人根據規則13a-16或15d-16提交報告）
**事件重點**：Lakefront Biotherapeutics NV（Euronext & NASDAQ: LKFT）於2026年6月29日發佈新聞稿，披露收到主要股東 Madison Avenue Partners 的透明度通知。該通知顯示，Madison Avenue Partners 及其關聯方（包括 Madison Avenue International, LP、EMAI Management, LLC 及 Eli Samaha）於2026年6月15日合計持有 Lakefront 投票權超過5%門檻，並於6月24日正式提交通知。
**關鍵數字**：
- 跨越門檻日期：2026年6月15日
- 通知日期：2026年6月24日
- 通知時直接持有投票權：3,498,892 股
- 佔已發行投票權百分比：5.31%
- 分母（已發行股份總數）：65,897,071 股
- 無等值金融工具持有（0.00%）
**事件背景**：此申報符合比利時透明度法規（2007年5月2日法案），主要股東因收購股份而觸發披露義務。通知中明確指出跨越門檻原因為收購投票證券或投票權。Madison Avenue Partners 在通知中亦披露了最終控制鏈（詳見原文第11節）。
**對投資者的潛在影響**：
- 此為常規股權披露，反映 Madison Avenue Partners 被動或主動增持 Lakefront 股份至5%以上，可能顯示機構投資者對公司前景的信心。
- 持股比例仍未達收購要約或控制權變更門檻，短期內對公司營運及管理層無直接影響。
- 投資者宜關注後續是否進一步增持或申報，以及 Madison Avenue Partners 的投資意圖（公告未說明被動/主動意圖）。
**關於 Lakefront Biotherapeutics**（公司簡介）：
Lakefront（前稱 Galapagos）是一家專注免疫學及炎症領域的臨床階段生物科技公司，核心資產 gamgertamig 為潛在首創 BCMAxCD3 T 細胞接合劑，用於自身免疫疾病。公司具備靈活的交易執行能力及強勁資本狀況，致力為患者及股東創造長期價值。
**總結**：此6-K申報主要為合規披露，無重大業務或財務變化。投資者需留意主要股東持股變動是否預示後續策略調整 🧐。
展開英文正文
EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Lakefront Receives Transparency Notification from Madison Avenue Partners Mechelen, Belgium; June 29, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Madison Avenue Partners. Pursuant to Belgian transparency legislation1, Lakefront received a transparency notification from Madison Avenue Partners on June 24, 2026. The notification indicates that Madison Avenue Partners, LP, jointly with Madison Avenue International, LP, EMAI Management, LLC, and Eli Samaha, crossed above the threshold of 5% of Lakefront’ voting rights on an aggregated basis on June 15, 2026, following the acquisition of Lakefront’ voting rights. On June 24, 2026, Madison Avenue Partners (taking into account the holding of its affiliates) owned 3,498,892 voting rights, representing 5.31% of Lakefront’ currently outstanding 65,897,071 shares. Summary of the transaction: Date on which the threshold was crossed Date of notification Direct voting rights after the transaction Equivalent financial instruments after the transaction Total (%)voting rights June 15, 2026 June 24, 2026 3,498,892 0.00% 5.31% Content of the notification from Madison Avenue Partners:The notification dated June 24, 2026, contains the following information:· Date of notification: June 24, 2026· Date on which the threshold is crossed: June 15, 2026· Threshold of voting rights crossed (in %): 5%· Notification by: Madison Avenue Partners· Denominator: 65,897,071· Reason for the notification: Acquisition or disposal of voting securities or voting rights· Notified details: A) Voting Rights Previous notification After the transaction # of voting rights # of voting rights % of voting rights Holder of voting rights Linked to securities Not linked to securities Linked to securities Not linked to securities Madison Avenue Partners, LP 0 3,498,892 5.31% B) Equivalent financial instruments After the transaction Holder of equivalent financial instruments Type of financial instrument Expiration date Exercise period or date # of voting rights that may be acquired if the instrument is exercised % of voting rights Settlement TOTAL 0 0.00% TOTAL (A&B) # of voting rights % of voting rights 3,498,892 5.31% The chain of control has been described at the end of the notification (section 11) and can be found here. About Lakefront® BiotherapeuticsLakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X. For further information, contact Lakefront Biotherapeutics:Investor Relations Sherri Spear+1 412 522 [email protected] 1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions, as amended from time to time.